Skip to main content
Medicine logoLink to Medicine
. 2016 May 13;95(19):e3498. doi: 10.1097/MD.0000000000003498

The Association between Baseline Subjective Anxiety Rating and Changes in Cardiac Autonomic Nervous Activity in Response to Tryptophan Depletion in Healthy Volunteers

Chih Yin Hsiao 1, Hsin Chun Tsai 1, Mei Hung Chi 1, Kao Chin Chen 1, Po See Chen 1, I Hui Lee 1, Tzung Lieh Yeh 1, Yen Kuang Yang 1
Editor: Helen Gharaei1
PMCID: PMC4902487  PMID: 27175645

Abstract

The aim of this study was to investigate the influence of serotonin on anxiety and autonomic nervous system (ANS) function; the correlation between subjective anxiety rating and changes of ANS function following tryptophan depletion (TD) in healthy volunteers was examined. Twenty-eight healthy participants, consisting of 15 females and 13 males, with an average age of 33.3 years, were recruited.

Baseline Chinese Symptom Checklist-90-Revised and ANS function measurements were taken. TD was carried out on the testing day, and participants provided blood samples right before and 5 hours after TD. ANS function, somatic symptoms, and Visual Analogue Scales (VASs) were determined after TD. Wilcoxon signed rank test and Spearman ρ correlation were adapted for analyses of the results.

The TD procedure reduced total and free plasma tryptophan effectively. After TD, the sympathetic nervous activity increased and parasympathetic nervous activity decreased. Baseline anxiety ratings positively correlated with post-TD changes in sympathetic nervous activity, VAS ratings, and physical symptoms. However, a negative correlation with post-TD changes in parasympathetic nervous activity was found.

The change in ANS function after TD was associated with the severity of anxiety in healthy volunteers. This supports the fact that the effect of anxiety on heart rate variability is related to serotonin vulnerability. Furthermore, it also shows that the subjective anxiety rating has a biological basis related to serotonin.

INTRODUCTION

Anxiety disorders contribute 3.5% of all years lived with disability,1 and have a high comorbidity with depression, hypertension,2 and cardiovascular disease.3 Previous studies have suggested that impaired regulation of the heart by the autonomic nervous system (ANS) involves pathophysiological links.4 ANS dysfunction, which can present as increased sympathetic activity or decreased parasympathetic activity, may also be related to higher peripheral somatosensory arousal and, in turn, to increased experience of somatic symptoms.5

The serotonergic neurons of the central nervous system (CNS) regulate mood, appetite, and sleep.6 A prominent role for serotonin (5-HT) in anxiety and depression is well acknowledged.78 Since 5-HT1A knockout mice have been found to exhibit abnormal maturation of cardiorespiratory control,9 serotonin might influence ANS regulation of the heart. Studies in animals have suggested that serotonergic projections to the periaqueductal gray region play an important role in suppressing the behavioral and autonomic correlates of panic.10

Through a combination of a low-protein diet and a tryptophan-free drink containing large neutral amino acids (LNAAs), the tryptophan depletion (TD) test has been proven to be an effective method of lowering the production of central serotonin.1115 During the test, the mean nadir of tryptophan was observed in the sixth hour after consumption.16 Subjects have been found to react differently to TD manipulation depending on their level of serotonin vulnerability.17 Previous research has shown that TD challenge leads to the exacerbation of transient symptoms, such as anxiety,1114,18 impulsivity,1920 and impaired decision-making,21 in several subgroups of patients, including those with generalized anxiety disorder (GAD), social anxiety disorder, substance abuse, attention deficit hyperactivity disorder (ADHD), and major depressive disorder (MDD).1114,1820,22

Reduced heart rate variability (HRV) has been proven to be a more useful measure of cardiac autonomic function than other peripheral markers, such as blood pressure or heart rate.2324 Reduced HRV has been observed not only in patients with chronic physical illnesses,2526 but also in patients suffering from anxiety disorders,2729 and in unmedicated MDD patients with comorbid GAD.30 Owing to multiple influencing factors, including the effects of medication and disease itself on HRV, there are no consistent data to support that serotonin activity has an effect on ANS function. HRV is not changed after sertraline loading in healthy volunteers.3132 In patients with other diagnoses, such as panic disorder or acute depression, antidepressant treatment did not consistently increase HRV.3335 Therefore, the effects of serotonin activity on anxiety and ANS function warrant further investigation.

Some TD studies have indicated that 5-HT has an effect on ANS function15,18,22; however, other studies have reported no effects.3637 Booji et al18 applied the Fourier transform cardiac ANS index in remitted depressed patients and found that TD decreased HRV only in those with a history of suicidal ideation. This implies that reduced HRV in depression after TD may be limited to individuals with characteristics such as impulsive or aggressive behaviors.

Most studies on the effect of serotonin on the ANS have been performed on patients with anxiety or depression disorders. Clarification of the relationship between anxiety and serotonin in healthy participants is necessary. This study aimed to examine correlates of the degree of reaction to TD in healthy volunteers. We hypothesized that the degree of change in cardiac ANS function after TD is associated with anxiety.

MATERIALS AND METHODS

Participants

Our study was conducted at National Cheng Kung University Hospital between 2010 and 2013 to explore serotonin vulnerability. In the cohort study of healthy people, participants were recruited through an advertisement approved by the ethical committee for human research. The inclusion criteria were (i) age 20 to 65 years; (ii) no past or current psychiatric disorder; (iii) no history of a psychiatric disorder in any first-degree relative; (iv) no major medical condition, such as cancer, heart disease, or organ failure; (v) no prescribed drugs that might interfere with the objectives of the study, such as beta blockers; and (vi) no history of illicit drug or psychoactive medication use, as confirmed by a negative urine screen. A senior psychiatrist conducted the Mini International Neuropsychiatric Interview with all participants.38 Totally, 43 participants were recruited in this cohort study. Only participants younger than 45 years (also applied to males for balance) were analyzed in this study to prevent any potential effect of menopause. The final sample consisted of 28 subjects (13 males, 15 females). Among the 15 participants excluded (5 males and 10 females), 11 were older than 45 years and 4 did not have baseline ANS recordings.

Procedures

Informed consent, demographic data (such as age, sex, and body mass index [BMI), Chinese Symptom Checklist-90-Revised (SCL-90-R) results, and ANS function data were obtained at baseline.

The TD challenge was administered to every participant, and was timed to coincide with the follicular phase in women. Participants adhered to a 24-hour low-protein diet and began fasting at 10:00 pm the night before the TD test. At 9:00 am on the day of testing, participants ingested the TD amino acid mixture. Blood samples for the measurement of total and free tryptophan were taken shortly before and 5 hours after administration of the drink. ANS function, somatic symptoms, and VASs related to TD were measured at 2:00 pm.

The amino acid drink was composed of 15 amino acids without l-tryptophan, as in previous studies.13,39 Because of their unpleasant taste, participants took the sulfur-containing amino acids (methionine, threonine, and arginine) in capsule form 15 minutes before consuming the remaining amino acids in drink form. The drink was prepared by mixing amino acid powder with 300 mL of room-temperature water. The amino acid solution was flavored with approximately 5 mL of chocolate-flavored syrup.

Assessments

Measurement of Cardiac Autonomic Function

Cardiac autonomic function was determined using an ANSWatch wrist monitor, which calculated the HRV (Taiwan Scientific Corporation, Taipei, Taiwan). This device employed multiple piezo-electrical sensors in the cuff to directly measure the blood pressure waveforms in the radial artery.

All the ANSWatch tests were performed in a quiet laboratory with soft light and a minimum level of stimulation to prevent any external influence on the participants. All participants were asked to avoid any activity for 60 minutes before the test, and sat quietly in the laboratory for at least 30 minutes before the test. Each ANSWatch test was completed within about 7 minutes. The data were then downloaded to a personal computer and analyzed using ANSWatch software. The accuracy of ANSWatch in terms of the correlation coefficient for HRV parameters was in the range of 0.90 to 1.0, as compared with the use of electrocardiography as the control.40

HRV was analyzed through frequency and time domain methods. The intervals between adjacent normal R waves (NN intervals) and the quantified cyclic fluctuations of R-R were measured over the recording period. The parameters were low frequency (LF, 0.04–0.15 Hz), high frequency (HF, 0.15–0.4 Hz), and LF/HF (ratio of LF to HF) in the frequency domain, as well as pNN50 (the proportion of NN50s in the total number of NNs, wherein NN50 is the number of pairs of successive NNs that differ by >50 ms) and the HRV triangular index in the time domain.23 LF is an index of sympathetic activity, whereas HF is an index of parasympathetic activity. The LF/HF ratio represents the sympathovagal balance. Higher LH/HF ratios reflect increased sympathetic activity or decreased parasympathetic modulation.41 pNN50 approximates to HF in the frequency domain.23,4243 The HRV triangular index resembles the total power as a total ANS activity index.44 ANSWatch testing was performed twice in this study, at both baseline and 5 hours post-TD.

Plasma Tryptophan Levels

Total and free tryptophan in plasma and the ratio of total tryptophan to LNAAs and tryptophan/LNAA were assessed to evaluate the efficacy of the TD procedure. Collected blood samples were centrifuged for 15 minutes at 4°C and 3000 rpm immediately. Plasma was frozen at –70°C until analysis. Immediately after thawing, 20 μL of 70% perchloric acid was added to 400 μL of plasma, followed by centrifugation for 30 minutes at 20,000g at 4°C, causing precipitation of the plasma proteins. To detect free tryptophan, plasma was filtered using an Amicon Ultra-0.5 Centrifuge Filter (10K device).45 Liquid chromatography-tandem mass spectrometry (API 2000 LC/MS/MS system) was used following a previously reported method46 to analyze the total and free tryptophan and other amino acids.

Psychological Assessment

The Chinese Symptom Checklist-90-Revised

This study used the Symptom Checklist-90-Revised (SCL-90-R, published by the Clinical Assessment division of the Pearson Assessment & Information group), a reliable and validated scale.4749 The checklist assesses the following 9 primary psychological symptoms: somatization, obsessive–compulsion, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, and psychoticism. Only the 10-item anxiety subscale was utilized in this study, with higher scores representing higher anxiety levels. A previous analysis reported that the SCL-90-R has a 76.5% hit rate in distinguishing anxiety disorder from depressive disorder: patients with anxiety scored more highly in the anxiety subscale.50

Somatic Symptoms

Our study adopted the Panic Attack Symptom Scale,51 which includes a list of somatic symptoms and has been used previously in TD research.13 Participants rated 23 symptoms on a 4-point scale (1, not at all; 2, mild; 3, moderate; and 4, severe). To analyze the number of somatic symptoms after TD, we recoded the scale into a 2-point scale (0, not at all; 1, mild to severe). Scale scores were summed, with higher scores representing greater severity of somatic symptoms after TD.

VASs for Mood States

We applied VASs that were adapted from previous research51 and have been used in other TD studies.11,1415 The participants rated the changes in 13 different mood states after TD: talkative, happy, sad, drowsy, anxious, nervous, energetic, calm, fearful, depressed, angry, high, and mellow. The scales were scored on a 0- (not at all) to 100-mm (most) line, wherein participants placed a perpendicular mark on the left-hand side that corresponded to his or her present state as compared with baseline.

Statistical Analysis

The data were analyzed using SPSS software 17.0 (SPSS Inc, Chicago, IL). Means and standard deviations (SDs) were calculated for the descriptive analysis of ANS function, both at baseline and after TD. Because the scores of the SCL-90-R anxiety subscale, VASs, somatic symptoms, and parameters of cardiac ANS functions were not of a normal distribution, nonparametric statistical analysis was conducted. The effects of age, sex, and BMI on the distributions of cardiac ANS function indexes in 3 conditions (baseline, after TD, and change rate) were examined by comparing the difference between groups (age: equal or above mean/under mean age [n: 17/11], sex: male/female [n: 13/15], BMI: obesity/nonobesity [n: 6/22], according to the standard of the Ministry of Health and Welfare in Taiwan). The Mann-Whitney U test was used in 2 groups’ comparison. The Wilcoxon signed rank test was adapted to compare baseline and post-TD ANS function. Two-tailed Spearman ρ correlation analysis was carried out to examine the associations between baseline anxiety score, VASs, somatic symptoms, and change in ANS function after TD.

RESULTS

The demographic characteristics of 28 participants are presented in Table 1.

TABLE 1.

Demographic Data and Baseline Anxiety Rating of 28 Participants

graphic file with name medi-95-e3498-g001.jpg

The TD procedure resulted in an 87.2% reduction in both total and free tryptophan, in addition to a 95.3% reduction in the tryptophan/LNAA ratio, which would result in an effective reduction in serotonin. After TD, the mean number of symptoms was 2.75 (range = 0–8; SD = 2.05), and disgust (n = 24, 86%), frequent urination (n = 12, 43%), and poor appetite (n = 10, 37%) were the most common symptoms. According to VAS rating, 7 participants (25%) experienced more anxiousness and 8 of them (28.6%) felt much nervous. Age and BMI did not affect the distributions of HRV indexes in all 3 conditions (Ps > 0.06) except obesity group with lower HRV triangular index (P = 0.04). Although females had higher HF, lower LF, and LF/HF at baseline and after TD compared with males (Ps < 0.011), no significant sex difference in pNN50 and HRV triangular index was noted (Ps > 0.37). The change rate of ANS functions in terms of these 5 indexes showed no sex difference (Ps > 0.46).

The comparison of HRV parameters at baseline and post-TD is shown in Table 2. PNN50, HRV triangular index, and HF all decreased following TD as compared with baseline, whereas LF and LF/HF increased. Indexes representing parasympathetic tone, such as pNN50 and the HF power spectrum, were significantly lowered following TD. Conversely, parameters related to the balance of sympathetic/parasympathetic activity, such as LF/HF, were higher after TD. Four of 5 effect sizes for changes in HRV indexes following TD showed medium effect (Table 2).

TABLE 2.

Comparison of Cardiac Autonomic Function at Baseline and After TD

graphic file with name medi-95-e3498-g002.jpg

The correlations between the baseline anxiety rating and cardiac ANS parameters, somatic symptoms, and VASs after TD are shown in Table 3. The baseline anxiety score was not significantly associated with any of the baseline cardiac ANS indexes. However, there were significantly negative correlations between the baseline anxiety score and the change rates in the following cardiac ANS parameters: pNN50 and HRV triangular index. In addition, a positive correlation between baseline anxiety score and LF/HF was also noted. Likewise, the baseline anxiety score was positively associated with subjective mood change in terms of the anxiety and nervousness VAS scoring, as well as symptoms after TD. The higher the anxiety score at baseline, the higher the VAS anxiety, the VAS nervousness rating, and the number of physical symptoms after TD.

TABLE 3.

Correlations Between SCL-90-R Anxiety Subscale at Baseline and Cardiac ANS Functions/Self-ratings (95% CI [in Parentheses])

graphic file with name medi-95-e3498-g003.jpg

DISCUSSION

In this study, the TD procedure reduced plasma tryptophan levels effectively, and this is in accordance with previous researches.13,16,52 Even all participants had received cardiac ANS function measurements through standardized procedure, as HRV indexes in our study had wide distributions, which also appeared in previous neurophysiology studies.53 Factors including age, sex, and BMI might influence the results of ANS functions, and should be considered and managed carefully. Most time- and frequency-domain indexes of HRV except LF/HF ratio decrease with age and these values further decrease until fourth decade of life.53 In our study, age did not affect the distribution of HRV significantly. One of the speculated reasons could be we had set a narrow range of age for inclusion to avoid the effects of menopause. The sex difference in the frequency-domain HRV indexes at baseline and following TD is in line with previous findings.53 However, there was no sex effect on the change ratio of HRV indexes in response to TD. As regarding to BMI, we only found the correlation with HRV triangular index; BMI was not related to the change ratio of any HRV index responding to TD as sex. Therefore, age, sex, and BMI were not needed to be controlled as confounding factors.

Following TD, the HRV triangular index and the power of HF decreased; however, the power of LF and the LF/HF ratio increased. This phenomenon indicates that the imbalance of sympathovagal tone and the attenuation of parasympathetic activity related to decreased central serotonin concentration are not only found in participants with depression or anxiety, as reported in previous research,15,18,35,5455 but also in healthy participants. Furthermore, the level of the decrease in parasympathetic nervous activity and the imbalance in sympathovagal tone after TD were correlated with the baseline anxiety rating in our healthy volunteers.

In addition to the previously reported reduction in HRV in individuals with anxiety disorders,2728 and in healthy volunteers with extreme trait anxiety,56 we found attenuated parasympathetic activity and reduced HRV induced by TD in our healthy volunteers without a personal or family history of psychiatric disorders or any complaints regarding ANS dysfunction. Although most previous research has concentrated on comparing the HRV with a control group, in this study, intraindividual comparisons were applied to measure ANS changes in healthy participants. The method reduced the effect of interference from medication or methodological issues. We speculate that the higher self-rated anxiety score in healthy people might be a marker of serotonin vulnerability.

The blood pressure variability caused by respiration would cause HRV via the arterial baroreflex because the reflex reacts to any blood pressure increase or decrease by a heart rate decrease or increase.57 According to Kellett et al,5859 serotonin depletion or 5-HT receptor blocking attenuates baroreflex gain. This mechanism could partly explain the reduced HRV observed following TD. Other mechanisms could also play roles, including reduced production of central serotonin, which influences the modulation of the limbic system through the 5-HT1A receptor,60 and a set of neural structures associated with emotional regulation, such as the prefrontal cortex.6162

The participants with higher anxiety scores not only gave higher self-reports of nervousness and physical symptoms after TD, but also had a decreased HRV index. Some studies have reported that the mood-lowering effect of TD may be because of the characteristics of participants,63 which implied a core problem of subjective reporting. The concordance of subjective self-reported VASs and symptoms with objective HRV measurements suggests that HRV is a suitable index for measurement of the effects of the TD procedure. Clinical rating scales might not be sensitive enough to detect psychological or somatic responses11,64; however, advanced tools such as functional brain imaging cannot be applied widely owing to cost and accessibility.21 In line with the findings that a reduced HRV is present in healthy volunteers both with recent stressful life events65 and task applications related to anxiety and depression,66 changes in HRV parameters have been suggested to be indicators of serotonin vulnerability in studies with a challenge test design.

Previous research has provided inconsistent findings on whether HRV is reduced because of the psychopathology of depression, or whether the reduction is driven by antidepressant medication. In a recent study, Kemp et al30 reported that HRV was reduced most in relation to comorbid GAD, not depression severity. Furthermore, previous evidence has suggested that anxiety, not depression, drives the reported HRV reductions in MDD.67 It has also been found that a reduced HRV in mice with a high anxiety trait can be reversed by anxiolytic drug treatment.68 The aforementioned evidence suggests the importance of investigating the role of anxiety in HRV, and accorded with our results regarding the effect of anxiety on HRV in situations of a decreased central serotonin level. To better understand the complicated pathology of ANS dysfunction in depression and anxiety patients, further research needs to take serotonin vulnerability into account.

Our results must be interpreted with caution because of the following potential limitations. First, the sample sizes were relatively small and the age range of the participants was limited to between 20 and 45 years. We were not able to compare the differences of demographic characteristics between the study subjects and those who declined or refused to join the study. Second, we did not include a placebo as a control for comparison with TD. Third, we applied the symptom checklist only after TD; the ratings were not used both pre- and post-TD. Lastly, the HRV level is sensitive to environmental and personal factors, which may not have been included.

In conclusion, our findings indicate that serotonin vulnerability could be a potential explanation for ANS dysfunction in healthy participants with higher baseline anxiety score. The effect of serotonin vulnerability on anxiety should be validated in further studies.

Acknowledgments

The authors would like to thank the National Science of Taiwan (NSC 93–2314-B-006–107, NSC 97–2314-B-006–006-MY3, NSC 101–2314-B-006–065), the National Cheng Kung University Hospital (NCKUH-9903019), and the Atomic Energy Council of Taiwan (NSC 99-NU-E-006–003) for their financial support. The authors also wish to thank Tsai Hua Chang and Chien Ting Lin from National Cheng Kung University Hospital for their administrative support.

Footnotes

Abbreviations: ADHD = attention deficit hyperactivity disorder, ANS = autonomic nervous system, BMI = body mass index, CNS = central nervous system, GAD = generalized anxiety disorder, HF = high frequency, HRV = heart rate variability, LF = low frequency, LNAA = large neutral amino acid, MDD = major depressive disorder, NN50 = the number of pairs of successive NNs that differ by more than 50 ms, pNN50 = the proportion of NN50 divided by total number of NNs, SCL-90-R = Symptom Checklist-90-Revised, SD = standard deviation, TD = tryptophan depletion, VAS = Visual analogue scale.

This research also received funding (D102–35001 and D103–35A09) from the Headquarters of University Advancement at the National Cheng Kung University, which is sponsored by the Ministry of Education, Taiwan, ROC.

The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

The authors declare that they have no conflicts of interest in relation to this work.

REFERENCES

  • 1.Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2163–2196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Carroll D, Phillips AC, Gale CR, et al. Generalized anxiety and major depressive disorders, their comorbidity and hypertension in middle-aged men. Psychosom Med 2010; 72:16–19. [DOI] [PubMed] [Google Scholar]
  • 3.Huang KL, Su TP, Chen TJ, et al. Comorbidity of cardiovascular diseases with mood and anxiety disorder: a population based 4-year study. Psychiatry Clin Neurosci 2009; 63:401–409. [DOI] [PubMed] [Google Scholar]
  • 4.Bajko Z, Szekeres CC, Kovacs KR, et al. Anxiety, depression and autonomic nervous system dysfunction in hypertension. J Neurol Sci 2012; 317:112–116. [DOI] [PubMed] [Google Scholar]
  • 5.Rief W, Shaw R, Fichter MM. Elevated levels of psychophysiological arousal and cortisol in patients with somatization syndrome. Psychosom Med 1998; 60:198–203. [DOI] [PubMed] [Google Scholar]
  • 6.Ressler KJ, Nemeroff CB. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 2000; 12:2–19. [DOI] [PubMed] [Google Scholar]
  • 7.Kahn RS, van Praag HM, Wetzler S, et al. Serotonin and anxiety revisited. Biol Psychiatry 1988; 23:189–208. [DOI] [PubMed] [Google Scholar]
  • 8.Graeff FG, Guimaraes FS, De Andrade TG, et al. Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem Behav 1996; 54:129–141. [DOI] [PubMed] [Google Scholar]
  • 9.Barrett KT, Kinney HC, Li A, et al. Subtle alterations in breathing and heart rate control in the 5-HT1A receptor knockout mouse in early postnatal development. J Appl Physiol (1985) 2012; 113:1585–1593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Deakin JF. Depression and 5HT. Int Clin Psychopharmacol 1991; 6 Suppl 3:23–28.discussion 29–31. [DOI] [PubMed] [Google Scholar]
  • 11.Argyropoulos SV, Hood SD, Adrover M, et al. Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder. Biol Psychiatry 2004; 56:503–509. [DOI] [PubMed] [Google Scholar]
  • 12.Davies SJ, Hood SD, Argyropoulos SV, et al. Depleting serotonin enhances both cardiovascular and psychological stress reactivity in recovered patients with anxiety disorders. J Clin Psychopharmacol 2006; 26:414–418. [DOI] [PubMed] [Google Scholar]
  • 13.Delgado PL, Charney DS, Price LH, et al. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990; 47:411–418. [DOI] [PubMed] [Google Scholar]
  • 14.Shufflebotham J, Hood S, Hendry J, et al. Acute tryptophan depletion alters gastrointestinal and anxiety symptoms in irritable bowel syndrome. Am J Gastroenterol 2006; 101:2582–2587. [DOI] [PubMed] [Google Scholar]
  • 15.van Veen JF, van Vliet IM, de Rijk RH, et al. Tryptophan depletion affects the autonomic stress response in generalized social anxiety disorder. Psychoneuroendocrinology 2009; 34:1590–1594. [DOI] [PubMed] [Google Scholar]
  • 16.Carpenter LL, Anderson GM, Pelton GH, et al. Tryptophan depletion during continuous CSF sampling in healthy human subjects. Neuropsychopharmacology 1998; 19:26–35. [DOI] [PubMed] [Google Scholar]
  • 17.Jans LA, Riedel WJ, Markus CR, et al. Serotonergic vulnerability and depression: assumptions, experimental evidence and implications. Mol Psychiatry 2007; 12:522–543. [DOI] [PubMed] [Google Scholar]
  • 18.Booij L, Swenne CA, Brosschot JF, et al. Tryptophan depletion affects heart rate variability and impulsivity in remitted depressed patients with a history of suicidal ideation. Biol Psychiatry 2006; 60:507–514. [DOI] [PubMed] [Google Scholar]
  • 19.Young SN, Regoli M, Leyton M, et al. The effect of acute tryptophan depletion on mood and impulsivity in polydrug ecstasy users. Psychopharmacology 2014; 231:707–716. [DOI] [PubMed] [Google Scholar]
  • 20.Kötting WF, Bubenzer S, Helmbold K, et al. Effects of tryptophan depletion on reactive aggression and aggressive decision-making in young people with ADHD. Acta Psychiatrica Scandinavica 2013; 128:114–123. [DOI] [PubMed] [Google Scholar]
  • 21.Daly E, Ecker C, Hallahan B, et al. Response inhibition and serotonin in autism: a functional MRI study using acute tryptophan depletion. Brain 2014; 137:2600–2610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.von Polier GG, Biskup CS, Kotting WF, et al. Change in electrodermal activity after acute tryptophan depletion associated with aggression in young people with attention deficit hyperactivity disorder (ADHD). J Neural Transm 2014; 121:451–455. [DOI] [PubMed] [Google Scholar]
  • 23.Malik M. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Circulation 1996; 93:1043–1065. [PubMed] [Google Scholar]
  • 24.Parati G, Mancia G, Di Rienzo M, et al. Point: cardiovascular variability is/is not an index of autonomic control of circulation. J Appl Physiol 2006; 101:676–678.discussion 681-672. [DOI] [PubMed] [Google Scholar]
  • 25.Coquet I, Mousson C, Rifle G, et al. Influence of ischemia on heart-rate variability in chronic hemodialysis patients. Ren Fail 2005; 27:7–12. [PubMed] [Google Scholar]
  • 26.Schroeder EB, Chambless LE, Liao D, et al. Diabetes, glucose, insulin, and heart rate variability: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care 2005; 28:668–674. [DOI] [PubMed] [Google Scholar]
  • 27.Blom EH, Olsson EM, Serlachius E, et al. Heart rate variability (HRV) in adolescent females with anxiety disorders and major depressive disorder. Acta Paediatr 2010; 99:604–611. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Licht CM, de Geus EJ, van Dyck R, et al. Association between anxiety disorders and heart rate variability in The Netherlands Study of Depression and Anxiety (NESDA). Psychosom Med 2009; 71:508–518. [DOI] [PubMed] [Google Scholar]
  • 29.Friedman BH, Thayer JF. Autonomic balance revisited: Panic anxiety and heart rate variability. J Psychosom Res 1998; 44:133–151. [DOI] [PubMed] [Google Scholar]
  • 30.Kemp AH, Quintana DS, Felmingham KL, et al. Depression, comorbid anxiety disorders, and heart rate variability in physically healthy, unmedicated patients: implications for cardiovascular risk. PLoS One 2012; 7:e30777. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Ahrens T, Frankhauser P, Lederbogen F, et al. Effect of single-dose sertraline on the hypothalamus-pituitary-adrenal system, autonomic nervous system, and platelet function. J Clin Psychopharmacol 2007; 27:602–606. [DOI] [PubMed] [Google Scholar]
  • 32.Siepmann M, Grossmann J, Muck-Weymann M, et al. Effects of sertraline on autonomic and cognitive functions in healthy volunteers. Psychopharmacology 2003; 168:293–298. [DOI] [PubMed] [Google Scholar]
  • 33.Prasko J, Latalova K, Diveky T, et al. Panic disorder, autonomic nervous system and dissociation - changes during therapy. Neuro Endocrinol Lett 2011; 32:641–651. [PubMed] [Google Scholar]
  • 34.Garakani A, Martinez JM, Aaronson CJ, et al. Effect of Medication and Psychotherapy on Heart Rate Variability in Panic Disorder. Depress Anxiety 2009; 26:251–258. [DOI] [PubMed] [Google Scholar]
  • 35.Bar KJ, Greiner W, Jochum T, et al. The influence of major depression and its treatment on heart rate variability and pupillary light reflex parameters. J Affect Disord 2004; 82:245–252. [DOI] [PubMed] [Google Scholar]
  • 36.Grippo AJ, Johnson AK. Biological mechanisms in the relationship between depression and heart disease. Neurosci Biobehav Rev 2002; 26:941–962. [DOI] [PubMed] [Google Scholar]
  • 37.Yeragani VK, Pohl R, Balon R, et al. Effect of imipramine treatment on heart rate variability measures. Neuropsychobiology 1992; 26:27–32. [DOI] [PubMed] [Google Scholar]
  • 38.Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59 Suppl 20:22–33.quiz 34-57. [PubMed] [Google Scholar]
  • 39.Delgado PL, Charney DS. Neuroendocrine challenge studies in affective disorders. London: Academic Press; 1991. [Google Scholar]
  • 40.Liang W, Yuan J, Sun D, et al. Changes in physiological parameters induced by indoor simulated driving: effect of lower body exercise at mid-term break. Sensors 2009; 9:6913–6933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Malliani A, Lombardi F, Pagani M, et al. Clinical exploration of the autonomic nervous system by means of electrocardiography. Ann N Y Acad Sci 1990; 601:234–246. [DOI] [PubMed] [Google Scholar]
  • 42.Bigger JT, Jr, Albrecht P, Steinman RC, et al. Comparison of time- and frequency domain-based measures of cardiac parasympathetic activity in Holter recordings after myocardial infarction. Am J Cardiol 1989; 64:536–538. [DOI] [PubMed] [Google Scholar]
  • 43.Kleiger RE, Stein PK, Bigger JT., Jr Heart rate variability: measurement and clinical utility. Ann Noninvasive Electrocardiol 2005; 10:88–101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Copie X, Hnatkova K, Staunton A, et al. Predictive power of increased heart rate versus depressed left ventricular ejection fraction and heart rate variability for risk stratification after myocardial infarction. Results of a two-year follow-up study. J Am Coll Cardiol 1996; 27:270–276. [DOI] [PubMed] [Google Scholar]
  • 45.Neumeister A, Nugent AC, Waldeck T, et al. Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls. Arch Gen Psychiatry 2004; 61:765–773. [DOI] [PubMed] [Google Scholar]
  • 46.Lee NC, Chien YH, Kobayashi K, et al. Time course of acylcarnitine elevation in neonatal intrahepatic cholestasis caused by citrin deficiency. J Inherit Metab Dis 2006; 29:551–555. [DOI] [PubMed] [Google Scholar]
  • 47.Derogatis LR, Cleary PA. Factorial invariance across gender for the primary symptom dimensions of the SCL-90. Br J Soc Clin Psychol 1977; 16:347–356. [DOI] [PubMed] [Google Scholar]
  • 48.Derogatis LR, Cleary PA. Confirmation of the dimensional structure of the scl-90: A study in construct validation. J Clin Psychol 1977; 33:981–989. [Google Scholar]
  • 49.Tsai MT, Wen JK, Lin HN, et al. Application of self-rating symptom scales to psychiatric outpatients. Chinese Society of the Neurology and Psychiatry Bulletin (Taipei) 1978; 4:47–56. [Google Scholar]
  • 50.Rief W, Fichter M. The Symptom Check List SCL-90-R and its ability to discriminate between dysthymia, anxiety disorders, and anorexia nervosa. Psychopathology 1992; 25:128–138. [DOI] [PubMed] [Google Scholar]
  • 51.Woods SW, Charney DS, Loke J, et al. Carbon dioxide sensitivity in panic anxiety. Ventilatory and anxiogenic response to carbon dioxide in healthy subjects and patients with panic anxiety before and after alprazolam treatment. Arch Gen Psychiatry 1986; 43:900–909. [DOI] [PubMed] [Google Scholar]
  • 52.Williams WA, Shoaf SE, Hommer D, et al. Effects of acute tryptophan depletion on plasma and cerebrospinal fluid tryptophan and 5-hydroxyindoleacetic acid in normal volunteers. J Neurochem 1999; 72:1641–1647. [DOI] [PubMed] [Google Scholar]
  • 53.Antelmi I, de Paula RS, Shinzato AR, et al. Influence of age, gender, body mass index, and functional capacity on heart rate variability in a cohort of subjects without heart disease. Am J Cardiol 2004; 93:381–385. [DOI] [PubMed] [Google Scholar]
  • 54.Koschke M, Boettger MK, Schulz S, et al. Autonomy of autonomic dysfunction in major depression. Psychosom Med 2009; 71:852–860. [DOI] [PubMed] [Google Scholar]
  • 55.Terhardt J, Lederbogen F, Feuerhack A, et al. Heart rate variability during antidepressant treatment with venlafaxine and mirtazapine. Clin Neuropharmacol 2013; 36:198–202. [DOI] [PubMed] [Google Scholar]
  • 56.Miu AC, Heilman RM, Miclea M. Reduced heart rate variability and vagal tone in anxiety: trait versus state, and the effects of autogenic training. Auton Neurosci 2009; 145:99–103. [DOI] [PubMed] [Google Scholar]
  • 57.Frederiks J, Swenne CA, TenVoorde BJ, et al. The importance of high-frequency paced breathing in spectral baroreflex sensitivity assessment. J Hypertens 2000; 18:1635–1644. [DOI] [PubMed] [Google Scholar]
  • 58.Kellett DO, Ramage AG, Jordan D. Central 5-HT7 receptors are critical for reflex activation of cardiac vagal drive in anaesthetized rats. J Physiol (Lond) 2005; 563:319–331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Kellett DO, Stanford SC, Machado BH, et al. Effect of 5-HT depletion on cardiovascular vagal reflex sensitivity in awake and anesthetized rats. Brain Res 2005; 1054:61–72. [DOI] [PubMed] [Google Scholar]
  • 60.Fisher PM, Meltzer CC, Ziolko SK, et al. Capacity for 5-HT1A-mediated autoregulation predicts amygdala reactivity. Nat Neurosci 2006; 9:1362–1363. [DOI] [PubMed] [Google Scholar]
  • 61.Davidson RJ. Lane RD, Nadel L. The functional neuroanatomy of affective style. Cognitive Neuroscience of Emotion. New York: Oxford University Press; 2000. 106–128. [Google Scholar]
  • 62.Thayer JF, Lane RD. A model of neurovisceral integration in emotion regulation and dysregulation. J Affect Disord 2000; 61:201–216. [DOI] [PubMed] [Google Scholar]
  • 63.Bell CJ, Hood SD, Nutt DJ. Acute tryptophan depletion. Part II: clinical effects and implications. Aust N Z J Psychiatry 2005; 39:565–574. [DOI] [PubMed] [Google Scholar]
  • 64.Stewart ME, Deary IJ, Ebmeier KP. Neuroticism as a predictor of mood change: the effects of tryptophan depletion. Br J Psychiatry 2002; 181:242–247. [DOI] [PubMed] [Google Scholar]
  • 65.Dishman RK, Nakamura Y, Garcia ME, et al. Heart rate variability, trait anxiety, and perceived stress among physically fit men and women. Int J Psychophysiol 2000; 37:121–133. [DOI] [PubMed] [Google Scholar]
  • 66.Shinba T, Kariya N, Matsui Y, et al. Decrease in heart rate variability response to task is related to anxiety and depressiveness in normal subjects. Psychiatry Clin Neurosci 2008; 62:603–609. [DOI] [PubMed] [Google Scholar]
  • 67.Rottenberg J. Cardiac vagal control in depression: a critical analysis. Biol Psychol 2007; 74:200–211. [DOI] [PubMed] [Google Scholar]
  • 68.Gaburro S, Stiedl O, Giusti P, et al. A mouse model of high trait anxiety shows reduced heart rate variability that can be reversed by anxiolytic drug treatment. Int J Neuropsychopharmacol 2011; 14:1341–1355. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Medicine are provided here courtesy of Wolters Kluwer Health

RESOURCES